Centaurus Financial Inc. Invests $1.87 Million in Halozyme Therapeutics, Inc. $HALO

Key Points

• Centaurus Financial acquired 23,928 Halozyme Therapeutics shares worth approximately $1.87 million, while institutional investors collectively own 97.79% of the company.
• Analyst sentiment remains favorable, with nine Buy ratings and an overall “Moderate Buy” consensus; the average price target is $91.20, though some firms recently raised targets as high as $115.
• Halozyme exceeded quarterly expectations, reporting $2.28 in EPS versus $1.79 expected and $481 million in revenue, up 47.7% year over year. The stock opened at $106.92, near its 12-month high of $109.66.

Centaurus Financial Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 23,928 shares of the biopharmaceutical company's stock, valued at approximately $1,873,000.

Other institutional investors have also modified their holdings of the company. Measured Wealth Private Client Group LLC lifted its holdings in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $28,000. Finally, Quantbot Technologies LP bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $30,000. Institutional investors own 97.79% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on HALO. Morgan Stanley lowered their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. TD Cowen raised their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Citigroup reissued a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Finally, HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $91.20.

Halozyme Therapeutics Stock Down 0.1%

HALO opened at $106.92 on Friday. The stock's 50 day moving average price is $86.27 and its 200 day moving average price is $74.57. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a market cap of $12.14 billion, a P/E ratio of 31.92, a P/E/G ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $109.66.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the company's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company's stock, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at $79,987,320.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock valued at $5,226,496 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source